Antibody-Drug Conjugates (ADCs) have unequivocally transformed the landscape of targeted oncology. By marrying the precision of monoclonal antibodies with the lethal potency of cytotoxic payloads, ADCs offer a "magic bullet" approach to cancer therapy. However, despite their clinical success, traditional bioconjugation methods—such as stochastic modification of lysine or cysteine...
Spanish 
English
Arabic
French
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek